Temporomandibular joint syndrome
ICD-10 M26.6 · ICD-11 DA0E.8

Treatment of Temporomandibular Joint Syndrome in Myogenous Temporomandibular Disorder

Clinical Scenario

This protocol addresses temporomandibular joint syndrome presenting as myogenous temporomandibular disorder (TMD) — a pattern characterised by pain and dysfunction of muscular origin. Evidence suggests that acupuncture or dry needling for individuals with myogenous TMD is likely to have a positive effect on pain symptoms.

Management Approach (Partial Overview)

For refractory myogenous TMD, the protocol focuses on injectable management. This includes a local anaesthetic-based approach targeting well-defined muscular sites, with a further injectable option considered in specific cases following senior clinical review and shared decision-making with the patient.

Full sequencing, selection criteria, and clinical decision points are in the complete protocol →
Instant Access to Structured Evidence-Based Regimens

References

  1. Evidence suggests acupuncture or dry needling for individuals with myogenous TMD is likely to have a positive effect on pain symptoms.
  2. For myogenous TMD with well-defined muscular trigger points, local anaesthetic trigger point injections may be beneficial in some individuals.
  3. As definitive evidence is lacking at this time, Botulinum toxin A should not be first line treatment.
  4. At present a therapeutic trial of Botulinum toxin A may be considered appropriate in individual myogenous TMD cases advocated by a senior clinician (consultant or specialist) and may require individual pharmacy approval for funding at a local level.
View source ↗